Alzheimer's Disease Research Center

The Alzheimer’s Disease Research Center (ADRC) at the Icahn School of Medicine at Mount Sinai is a comprehensive research facility and clinical program dedicated to the study and treatment of normal aging and Alzheimer’s disease. With research into the causes of dementia, diagnostic services, and caregiver programs, the ADRC seeks to improve diagnosis, delay disease progression, and enhance the well-being of those affected by Alzheimer's disease.

Meet The Director

Mary Sano, PhD

Director, Alzheimer’s Disease Research Program

Meet Our Team

Samuel E Gandy, MD, PhD

PROFESSOR

Alison M Goate, DPhil

PROFESSOR
PROFESSOR & CHAIR

Patrick R Hof, MD

PROFESSOR

View All Team

Recent News

Research During COVID: Music Therapy Study

Exciting Study Conducted Totally Remotely

STAT News: That Pathetic Alzheimer’s Pipeline? It’s Even Worse Than You Think — Sharon Begley

If it were any other disease, outraged patients and their families would be writing their legislators and demonstrating in front of drug makers’ headquarters.

New Alzheimer’s Drug Slows Memory Loss in Early Trial Results

The long, discouraging quest for a medication that works to treat Alzheimer’s reached a potentially promising milestone on Wednesday.

The Mercury News: Medicare Offers No Help For The High Costs Of Dementia Caregiving — Lisa M. Krieger

Families’ out-of-pocket costs for a patient with dementia are 80 percent higher than the cost for someone with heart disease or cancer.

Alzheimer’s & Dementia Weekly: Alzheimer’s & Vitamin E

Phone-Based Therapy Sessions May Help Dementia Caregivers Cope — Cheryl Platzman Weinstock

New Scientist: AI Spots Alzheimer’s Brain Changes Years Before Symptoms Emerge — Anil Ananthaswamy

Scientific American: What Would It Take To Get An Effective Alzheimer’s Drug? — Samuel Gandy, MD, PhD, Mary Sano, PhD, Tamas Bartfai, Graham Lees

US News & World Report: Why Cognitive Impairment Is More Common When You Have Diabetes — Vanessa Caceres

In Small Alzheimer’s Study, Hints Of Modest Benefit From Unusual Drug

A little-known drug company announced modestly encouraging results for its experimental Alzheimer’s drug, a rare but preliminary glimmer of hope in a field that has been battered by failure after failure.

Midlife Vascular Risk Factors Tied to Brain Amyloid - Kristina Fiore

Having more vascular risk factors in middle age was associated with greater brain amyloid deposition in later life, researchers found.

Lack of Exercise Might Invite Dementia

Dr. Samuel Gandy, Director of Center for Cognitive Health at Mount Sinai featured on a HealthDay article discussing a study that being sedentary may make you as vulnerable as those whose genes put them at risk for Alzheimer's.